UPDATE: Ebos outlook subdued after Symbion acquisition driven profit boost

UPDATE: Ebos outlook subdued after Symbion acquisition driven profit boost
(Adds investor comment, share price) By Suze Metherell Aug. 27 (BusinessDesk) - Ebos Group is unlikely to repeat a trebling of annual profit fuelled by last year acquisition of the Symbion pharmaceutical wholesaler and distributor in Australia, where regulatory changes are putting pressure on the sector. The $1.1 billion cash and scrip Symbion purchase in June 2013 was a game-changer for the Christchurch-based healthcare and animal care manufacturer company, more than tripling annual revenue in a deal that gave Symbion’s owner Zuellig...